Barleria as a Platform for Innovation in Science and Technology: From Botanical Diversity to Translational Drug Discovery
Fuente:
Zenodo
Salvato in:
| Autori principali: | , |
|---|---|
| Natura: | Recurso digital |
| Lingua: | inglese |
| Pubblicazione: |
Zenodo
2026
|
| Soggetti: | |
| Accesso online: | |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| _version_ | 1866901400783421440 |
|---|---|
| author | Sagar S. Bawake Prasad Y. Lamrood |
| author_facet | Sagar S. Bawake Prasad Y. Lamrood |
| contents | <p class="MsoNormal"><span>The integration of traditional botanical knowledge with modern scientific and technological tools has become a major driver of innovation in contemporary life sciences. The genus <em>Barleria </em>L. (family Acanthaceae) exemplifies this convergence by combining taxonomic diversity, chemical complexity, and emerging technological applications in drug discovery. Distributed mainly across Africa, the Indian subcontinent, and Southeast Asia, <em>Barleria</em> comprises approximately 250–300 species with wide ecological adaptability and long-standing ethnomedicinal relevance (Balkwill & Balkwill, 1998; Darbyshire et al., 2010; McDade et al., 2018).</span></p> <p class="MsoNormal"><span>Recent advances in phytochemistry, mechanistic pharmacology, and computational biology have revealed a rich repertoire of bioactive secondary metabolites, including iridoid glycosides, flavonoids, and terpenoids, with demonstrated anti-inflammatory, antimicrobial, antidiabetic, and hepatoprotective activities (Bawake & Gaykar, 2022). Computational approaches such as molecular docking, molecular dynamics simulations, and in silico ADMET prediction have accelerated lead identification and improved mechanistic understanding, highlighting the genus as a promising source of phytopharmaceutical candidates (Li et al., 2022; Patel et al., 2024).</span></p> <p class="MsoNormal"><span>Despite strong preclinical evidence, translational challenges persist, particularly in standardization, pharmacokinetic validation, and clinical evaluation. This manuscript presents <em>Barleria</em> as an innovative botanical model, illustrating how interdisciplinary integration of taxonomy, chemistry, pharmacology, and digital technologies can contribute to future science- and technology-driven therapeutic development.</span></p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_19667332 |
| institution | Zenodo |
| language | eng |
| publishDate | 2026 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Barleria as a Platform for Innovation in Science and Technology: From Botanical Diversity to Translational Drug Discovery Sagar S. Bawake Prasad Y. Lamrood Barleria, Acanthaceae, iridoid glycosides, medicinal plants, pharmacological activity, molecular docking, phytochemistry. <p class="MsoNormal"><span>The integration of traditional botanical knowledge with modern scientific and technological tools has become a major driver of innovation in contemporary life sciences. The genus <em>Barleria </em>L. (family Acanthaceae) exemplifies this convergence by combining taxonomic diversity, chemical complexity, and emerging technological applications in drug discovery. Distributed mainly across Africa, the Indian subcontinent, and Southeast Asia, <em>Barleria</em> comprises approximately 250–300 species with wide ecological adaptability and long-standing ethnomedicinal relevance (Balkwill & Balkwill, 1998; Darbyshire et al., 2010; McDade et al., 2018).</span></p> <p class="MsoNormal"><span>Recent advances in phytochemistry, mechanistic pharmacology, and computational biology have revealed a rich repertoire of bioactive secondary metabolites, including iridoid glycosides, flavonoids, and terpenoids, with demonstrated anti-inflammatory, antimicrobial, antidiabetic, and hepatoprotective activities (Bawake & Gaykar, 2022). Computational approaches such as molecular docking, molecular dynamics simulations, and in silico ADMET prediction have accelerated lead identification and improved mechanistic understanding, highlighting the genus as a promising source of phytopharmaceutical candidates (Li et al., 2022; Patel et al., 2024).</span></p> <p class="MsoNormal"><span>Despite strong preclinical evidence, translational challenges persist, particularly in standardization, pharmacokinetic validation, and clinical evaluation. This manuscript presents <em>Barleria</em> as an innovative botanical model, illustrating how interdisciplinary integration of taxonomy, chemistry, pharmacology, and digital technologies can contribute to future science- and technology-driven therapeutic development.</span></p> |
| title | Barleria as a Platform for Innovation in Science and Technology: From Botanical Diversity to Translational Drug Discovery |
| topic | Barleria, Acanthaceae, iridoid glycosides, medicinal plants, pharmacological activity, molecular docking, phytochemistry. |
| url | https://doi.org/10.5281/zenodo.19667332 |